

CJC-1295 without DAC (Modified GRF 1-29) — Research Summary

Research Use Only. Not for human consumption. For laboratory/research reference purposes only.

Part of the Prolific Peptides Research Library — a summary of published third-party research, provided for informational and research purposes only. This content is separate from product listings and does not constitute a claim about any Prolific Peptides product's effects.

1. What It Is

CJC-1295 without DAC — also called Modified GRF(1-29) or Mod GRF 1-29 — is the same tetra-substituted, DPP-IV-resistant GHRH(1-29) analog as CJC-1295, but without the albumin-binding maleimidopropionyl linker.

Without the DAC modification, plasma half-life is approximately 30 minutes rather than 6–8 days, producing a short, discrete GH pulse rather than sustained elevation. This shorter-acting profile is the form most often paired with GH secretagogues in published mechanistic work (see Ipamorelin blend entry).

2. Reported Effects in Research Literature

Reminder: Research Use Only. Not for human consumption. The following is a summary of published research findings, not a therapeutic claim.

- Animal data: Early rat dosing studies (cited in FDA docket correspondence referencing the original ConjuChem pharmacology work) found the tetrasubstituted hGRF(1-29) backbone produced a roughly 4-fold increase in GH area-under-curve over native hGRF(1-29) over a 2-hour window.
- Human/mechanistic data: Published characterization work distinguishes the ~30-minute half-life, pulsatile-release profile of the no-DAC form from the multi-day, sustained-release profile of CJC-1295 with DAC — the two are pharmacokinetically distinct and not directly interchangeable in published research designs.

3. Clinical & Preclinical Study References

Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. (Foundational pharmacology characterizing the hGRF(1-29) backbone shared by both DAC and no-DAC forms.)

Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683 (DAC-form human PK/PD data, referenced for backbone comparison).

Regulatory/Safety Note: No FDA-approved product exists for this compound in any form; it is classed as a research chemical with no completed controlled human efficacy trials specific to the non-DAC form.

This compound has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease in humans or animals.

This document is for informational and research purposes only. It does not constitute medical advice, dosing guidance, or an endorsement of human or veterinary use. For full terms governing research use, see our RUO Policy at ProlificPeptides.com.

This summary may not be reproduced, excerpted, or used as product labeling or marketing copy without written permission from Prolific Peptides, LLC.

Regulatory and research-status information reflects publicly available sources as of September 7, 2026, and may change.